Glycogen Synthase Kinase 3: A Point of Integration in Alzheimer's Disease and a Therapeutic Target?
Glycogen synthase kinase 3 (GSK3) has been implicated in neurological disorders; therefore, it is not surprising that there has been an increased focus towards developing therapies directed to this kinase. Unfortunately, these current therapies have not taken into consideration the physiological rol...
Main Authors: | Siddhartha Mondragón-Rodríguez, George Perry, Xiongwei Zhu, Paula I. Moreira, Sylvain Williams |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2012-01-01
|
Series: | International Journal of Alzheimer's Disease |
Online Access: | http://dx.doi.org/10.1155/2012/276803 |
Similar Items
-
Amyloid Beta and Tau Proteins as Therapeutic Targets for Alzheimer’s Disease Treatment: Rethinking the Current Strategy
by: Siddhartha Mondragón-Rodríguez, et al.
Published: (2012-01-01) -
Glycogen synthase kinase-3: A promising therapeutic target for Fragile X Syndrome
by: Marjelo M. Mines, et al.
Published: (2011-11-01) -
Glycogen Synthase Kinase-3
by: Peter Crouch, et al.
Published: (2011-01-01) -
Targeting Glycogen Synthase Kinase-3β for Therapeutic Benefit against Oxidative Stress in Alzheimer's Disease: Involvement of the Nrf2-ARE Pathway
by: Katja Kanninen, et al.
Published: (2011-01-01) -
Regulation of Cell Survival Mechanisms in Alzheimer's Disease by Glycogen Synthase Kinase-3
by: Marjelo A. Mines, et al.
Published: (2011-01-01)